feed,title,long_url,short_url
MedRxiv,Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection,https://medrxiv.org/cgi/content/short/2022.03.29.22272714v1?rss=1,https://bit.ly/36JAGLf
MedRxiv,"Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a phase 1/2, randomized, placebo-controlled, observer-blinded trial",https://medrxiv.org/cgi/content/short/2022.03.30.22273143v1?rss=1,https://bit.ly/3iWsWYC
